Loading…
Transcode Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in RNAZ.
▼ -100.0% over 5Y.
today you would have $0.00▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $6.83 | $94.36 | $6,098.40 | $497,481.59 | $1,877,568.00 | |
| P/B | 2.4x | 0.6x | — | 23.4x | 3.2x | 1.6x |
| EPS | -$52.59 | -$1,336.63 | -$95,732.28 | -$1,000,497.96 | -$598,752.00 | |
| ROE | -438.69% | -335.36% | — | -1130.30% | -542.01% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CRISCuris Inc | $0.95 | 0.3x | 0.4x | — | — | $2.31M |
| OGENOragenics Inc | $0.52 | 0.5x | 0.4x | — | -1307.06% | $2.37M |
| VRAXVirax Biolabs Group Ltd | $2.82 | — | 0.2x | — | -78.65% | $2.25M |
| ONCOOnconetix, Inc. | $0.61 |
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor. The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Company description provided by Yahoo Finance.
| -33.54% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| 0.0x |
| 0.2x |
| — |
| -105.23% |
| $2.42M |
| IVFINVO Fertility, Inc. | $1.00 | 0.0x | 0.1x | — | -55.28% | $2.51M |
| AKANAkanda Corp | $3.89 | — | — | — | — | $2.1M |